Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer
View/ Open
Author
Aleksandrova, Krasimira
Boeing, Heiner
Nöthlings, Ute
Jenab, Mazda
Fedirko, Veronika
Kaaks, Rudolf
Lukanova, Annekatrin
Trichopoulou, Antonia
Boffetta, Paolo
Trepo, Elisabeth
Westhpal, Sabine
Duarte-Salles, Talita
Stepien, Magdalena
Overvad, Kim
Tjønneland, Anne
Halkjær, Jytte
Boutron-Ruault, Marie-Christine
Dossus, Laure
Racine, Antoine
Bamia, Christina
Benetou, Vassiliki
Agnoli, Claudia
Palli, Domenico
Panico, Salvatore
Tumino, Rosario
Vineis, Paolo
Bueno-de-Mesquita, Bas
Peeters, Petra H
Gram, Inger Torhild
Lund, Eiliv
Weiderpass, Elisabete
Quirós, J Ramón
Agudo, Antonio
Sánchez, María-José
Gavrila, Diana
Barricarte, Aurelio
Dorronsoro, Miren
Ohlsson, Bodil
Lindkvist, Björn
Johansson, Anders
Sund, Malin
Khaw, Kay-Tee
Wareham, Nicholas
Travis, Ruth C
Riboli, Elio
Pischon, Tobias
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1002/hep.27016Metadata
Show full item recordCitation
Aleksandrova, K., H. Boeing, U. Nöthlings, M. Jenab, V. Fedirko, R. Kaaks, A. Lukanova, et al. 2014. “Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.” Hepatology (Baltimore, Md.) 60 (3): 858-871. doi:10.1002/hep.27016. http://dx.doi.org/10.1002/hep.27016.Abstract
Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years, 296 participants developed HCC (n = 125), GBTC (n = 137), or IBD (n = 34). Using risk-set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age, sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. After adjustment for lifestyle factors, diabetes, hepatitis infection, and adiposity measures, higher concentrations of CRP, IL-6, C-peptide, and non-HMW adiponectin were associated with higher risk of HCC (IRR per doubling of concentrations = 1.22; 95% CI = 1.02-1.46; P = 0.03; 1.90; 95% CI = 1.30-2.77; P = 0.001; 2.25; 95% CI = 1.43-3.54; P = 0.0005; and 2.09; 95% CI = 1.19-3.67; P = 0.01, respectively). CRP was associated also with risk of GBTC (IRR = 1.22; 95% CI = 1.05-1.42; P = 0.01). GLDH was associated with risks of HCC (IRR = 1.62; 95% CI = 1.25-2.11; P = 0.0003) and IBD (IRR = 10.5; 95% CI = 2.20-50.90; P = 0.003). The continuous net reclassification index was 0.63 for CRP, IL-6, C-peptide, and non-HMW adiponectin and 0.46 for GLDH, indicating good predictive ability of these biomarkers. Conclusion:: Elevated levels of biomarkers of inflammation and hyperinsulinemia are associated with a higher risk of HCC, independent of obesity and established liver cancer risk factors. (Hepatology 2014;60:858–871)Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231978/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581098
Collections
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)